AstraZeneca announces multibillion dollar investments in China as Big Pharma is increasingly looking east for innovation.

Under the deal, the FTSE 100 group will have the exclusive global rights, outside China, to CSPC's once-a-month jab that is about to start early-stage clinical trials.

If you are wondering whether AstraZeneca shares are offering fair value at current levels, this breakdown will help you connect the recent share price with what the underlying business might justify.

NEW YORK CITY, NEW YORK / ACCESS Newswire / January 30, 2026 / Precidian Funds today announced that AstraZeneca PLC ADRhedged™ (the "Series") will liquidate following AstraZeneca PLC's announcement th ...

CSPC said earlier Friday that it entered an obesity drug agreement with AstraZeneca that would give the U.K.-based pharmaceutical company rights outside China to its clinical-ready long-acting obesity ...

Back in London, Saga was the top performer on the FTSE 250, up 3.5% after Deutsche Bank Research raised its price target to 600 pence from 285 pence and reiterated a 'buy' rating. Man Group followed, ...

AstraZeneca ( AZN) has struck an obesity drug deal with Chinese company CSPC Pharmaceutical Group ( CHJTF) worth up to $18.5B ...

According to fund sponsor T. Rowe Price, managers invest in four main categories: Pharmaceuticals, health care companies, ...

AstraZeneca announces a $15B China investment through 2030 to expand manufacturing and R&D in cell therapy and radioconjugates—read the full update now.

UK drugmaker AstraZeneca will invest $15 billion in China through 2030 to expand medicines manufacturing and research and ...

Fintel reports that on January 27, 2026, Citigroup initiated coverage of AstraZeneca PLC - Depositary Receipt (NasdaqGS:AZN) ...

AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory review after strong trial results.